AVRO News and Press, AVROBIO Inc. From 02/04/22

Avrobio (NASDAQ:AVRO) granted non-statutory stock options for the purchase of up to 167K shares to three new employees; it granted 2,667 restricted stock units to one new employee. The stock options and RSUs were granted with an exercise price of $1.95/share for each stock option. The stock o...

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced the appointment of Sean O’Bryan as chief regulatory officer. Sean brings a wealth of experience in regulatory s...

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO, will present virtually at Cowen’s 2 nd Annual ...

Analyst and investor conference call scheduled for Wednesday, Feb. 9, 2022, at 8:00 a.m. ET Five platform presentations and three posters on the company’s clinical and preclinical programs for lysosomal disorders are scheduled throughout the symposium AVROBI...

AVROBIO Inc ( NASDAQ: AVRO ) dropped by 30% after announcing it was changing its portfolio priorities to concentrate on other clinical-stage pipeline programs. The company plans to deprioritize the Fabry program because of several reasons, including new clinical findings from th...

Fabry disease program to be deprioritized, shifting focus to other clinical-stage programs in lysosomal disorder pipeline Data updates for cystinosis and Gaucher disease type 1 programs planned for 1H 2022, with regulatory interactions anticipated across multiple programs in 2...

Safety data updates for Phase 1 and 2 Fabry disease clinical trials and Phase 1/2 Gaucher disease type 1 clinical trial show no adverse events or serious adverse events related to drug product AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company wi...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences: Barclays...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will present safety data from its clinical trials in Fabry disease and Gaucher disease type 1 at the 14 th Inter...

Provided comprehensive safety update on AVROBIO’s lentiviral gene therapy platform and programs at ESGCT 2021 Received FDA feedback on CMC requirements for anticipated Fabry disease registration trial; registration study initiation anticipated for mid-2022 Cash ...